PortfolioPlus
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige

Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partner 05.08.2026, 10:30 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Santen Pharmaceutical 10,15 EUR -2,87 % L&S Exchange

Santen Pharmaceutical Co., Ltd.
Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partner

05-Aug-2026 / 10:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Santen Joins Inaugural Global Summit for Eye Health
as High-Impact Partner

 


Osaka, Japan – 5 August 2026 – (JCN Newswire) – Santen Pharmaceutical Co., Ltd. today announced it will join the inaugural Global Summit for Eye Health as a High Impact Partner, marking another step in the company’s long-standing commitment to advancing eye health worldwide.
 

 

Organized by the International Agency for the Prevention of Blindness (IAPB) in technical collaboration with the World Health Organization (WHO), the Summit will bring together heads of government, ministers, international organizations, civil society, and private-sector leaders in Antigua & Barbuda, a Caribbean island nation on 2 November 2026.

Together, they will launch the Global Eye Health Compact, a new global framework designed to accelerate progress through measurable commitments from governments and organizations.

As a High Impact Partner, Santen helps shape the Global Eye Health Compact and, at the Summit, will unveil its global eye health commitment, outlining how the company will contribute to improving eye health over the coming years.

Despite being essential to education, employment, independence, and healthy aging, eye health remains one of the world’s most overlooked public health challenges. More than one billion people worldwide continue to live with avoidable vision impairment*, highlighting a critical gap between available solutions and access to care.  Addressing this challenge requires coordinated action across prevention, early diagnosis, treatment, and public policy.

Rie Nakajima, Director of the Board, Chief Operating Officer of Santen Global, commented:

“No single organization can solve the growing burden of vision impairment alone. By working alongside governments, healthcare professionals, patient organizations, and global partners, we can help strengthen eye health systems, improve access to quality eye care, and deliver lasting benefits for people around the world. With more than 135 years of dedication to eye health, Santen is proud to join this global coalition.”

Santen’s participation builds on its longstanding collaboration with IAPB and partners across the eye health community to strengthen policy, raise awareness, and promote early action, including initiatives to advance childhood myopia and encourage healthy eye health habits for children.

Peter Holland, CEO, IAPB, commented:

“We welcome Santen’s participation in the first Global Summit for Eye Health and look forward to continuing our collaboration to strengthen eye health policies and improve outcomes for over 1 billion people who experience vision problems worldwide. Only by working together like this can we deliver eye care services at scale and speed to end avoidable or treatable sight loss.”

 

* https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment

 

 

About Santen

Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health, and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen’s products and services are available in more than 60 countries and regions. Guided by its Core Principle “Tenki ni sanyo suru” – Exploring the secrets and mechanisms of nature in order to contribute to people’s health – Santen combines its expertise with deep patient focus to contribute to the realization of “Happiness with Vision.” For more information, please visit https://www.santen.com/en

 

About the Global Summit of Eye Health

On 2 November, Antigua and Barbuda will host the world’s first Global Summit for Eye Health — the moment when governments, partners and global leaders unite for the first time to ensure everyone, everywhere can access the eye care they need. At the Summit, countries will set out concrete commitments to strengthen eye health services worldwide, aligning global action and accelerating progress to help reach over 1 billion people living with avoidable sight-loss. For more information, please visit Global Summit for Eye Health - Making the world see the value of vision

 

 

About IAPB

IAPB is the overarching alliance for the global eye health sector, with more than 250 member organisations in over 100 countries working together for a world where everyone has universal access to eye care. IAPB believes in a world in which no one is needlessly visually impaired, where everyone has access to the best possible standard of eye health; and where those with irreparable sight loss achieve their full potential. Its key priorities are global advocacy, campaigning on a different level, sharing knowledge, and strengthening the network: www.iapb.org.

 

Partnership Transparency Statement

Santen supports the activities described in this initiative through collaboration with IAPB. The organizations maintain independent governance and decision-making. The views expressed by IAPB are its own and do not necessarily reflect those of Santen.

 

The media toolkit:

For media inquiries:

Santen Pharmaceutical Co., Ltd.

Corporate Communications

Email: communication@santen.com

###

 

rie
Rie Nakajima
Director of the Board,
Corporate Officer,
Chief Operating Officer 

Rie Nakajima joined Santen in 2023 as Executive Officer and Chief Operating Officer (COO), and was appointed as a Director of the Board  in June 2024. She oversees strategic functions such as corporate strategy and portfolio management, as well as execution functions including commercial excellence. In addition, by managing regional businesses, she drives strategic global operations.
Prior to joining Santen, she built a diverse career spanning more than 20 years across the automotive industry, management consulting, and the pharmaceutical sector. In the pharmaceutical industry, she held leadership roles in global organizations in Japan, Asia, and Europe, primarily in corporate strategy and commercial excellence.

Profile
Date of Birth: December 12, 1977


Apr 2000   Joined Toyota Motor Corporation
Aug 2008   Joined Boston Consulting Group
Aug 2011   Joined MSD K.K.
Jan 2015   Head of Marketing, Cardiovascular Lipid & Atherosclerosis Division, MSD K.K.
Jun 2016   Executive Officer, Head of Corporate Strategy Division and Established Products Business, MSD K.K.
Jan 2018   Executive Officer, Head of Corporate Strategy & Commercial Excellence Division and Established Products Business, and Distribution Lead, MSD K.K.
Jan 2019   President, MSD Taiwan
Nov 2020   Vice President, Organon Strategy & Innovation Lead, Merck & Co., Inc.
Jun 2021   Vice President, Strategy & Innovation Lead, Organon & Co.
Mar 2023   Joined Santen as Executive Officer, COO
Jun 2023   Corporate Officer, COO and Head of North America Business
Apr 2024   Corporate Officer, COO and Head of China Business
Jun 2024   Director of the Board, Corporate Officer, COO

Education

Mar 2000   Graduated from the Faculty of Law, the University of Tokyo

Jun 2007   Master of Business Administration (MBA), Harvard Business School



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

View original content: EQS News


End of Announcement - EQS News Service

2377850  05-Aug-2026 

Kommentare (0) ... diskutiere mit.
Werbung

Ihre Lieblingsaktie geschenkt

BörsenNEWS.de und Smartbroker+ starten gemeinsam eine exklusive Bonus-Aktion. Eröffnen Sie bis 31.08.2026 ein Depot bei Smartbroker+ und erhalten als Willkommensgeschenk einen Anteil ausgewählter Aktien im Wert von 50 Euro!.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer